Candel Therapeutics, Inc.

NASDAQ:CADL

4.98 (USD) • At close April 25, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 00001.7760000.0310.0310.0310.0310.0310.0310.0310.0310.0310.0310.0310.031
Cost of Revenue 000.2490.2510.3120.3060.29500.2760.2580.2380.2150.1785.2653.2922.753001.7951.621
Gross Profit 00-0.249-0.2511.464-0.306-0.2950-0.245-0.227-0.207-0.184-0.147-5.234-3.261-2.7220.0310.031-1.764-1.59
Gross Profit Ratio 00000.824000-7.903-7.323-6.677-5.935-4.742-168.839-105.194-87.80611-56.903-51.29
Reseach & Development Expenses 4.8175.4164.9793.8516.9465.8455.9345.4694.9725.3765.0225.4173.8545.2653.2922.7533.5341.8131.7951.621
General & Administrative Expenses 3.3243.3413.5923.83.063.0163.6454.1643.163.5363.7623.63.9172.7952.041.9352.6220.9670.8550.728
Selling & Marketing Expenses 00000000000000000000
SG&A 3.3243.3413.5923.83.063.0163.6454.1643.163.5363.7623.63.9172.7952.041.9352.6220.9670.8550.728
Other Expenses 00000.012000-0.0485.3454.9915.38615.98-8.25-12.369-0.191-4.553-0.154-0.5070.455
Operating Expenses 8.1418.7578.5717.65110.0068.8619.5679.6338.0848.9128.7849.0177.6227.9294.7274.4976.0052.6262.4942.186
Operating Income -8.141-8.757-8.571-7.902-10.318-8.861-9.579-9.633-8.101-8.881-8.753-8.986-7.74-8.029-5.301-4.657-6.125-2.749-2.619-2.318
Operating Income Ratio 0000-5.81000-261.323-286.484-282.355-289.871-249.677-259-171-150.226-197.581-88.677-84.484-74.774
Total Other Income Expenses Net -5.932-1.889-13.666-0.319-0.7770.426-0.0350.8383.0180.1934.6048.1129.336-8.133-11.7790.179-4.3530.195-0.2570.546
Income Before Tax -14.073-10.646-22.237-8.221-11.095-8.435-9.614-8.795-5.083-8.688-4.149-0.8741.596-16.162-17.08-4.478-10.478-2.554-2.876-1.772
Income Before Tax Ratio 0000-6.247000-163.968-280.258-133.839-28.19451.484-521.355-550.968-144.452-338-82.387-92.774-57.161
Income Tax Expense 0000.2080.386-0.090.6440-15.735-0.193-4.604-8.1120.0120.0140.0150.1914.5040.1540.4130.072
Net Income -14.073-10.646-22.237-8.221-11.095-8.435-9.614-8.79510.652-8.4950.4557.2381.596-16.162-17.08-4.478-10.478-2.554-2.876-1.772
Net Income Ratio 0000-6.247000343.613-274.03214.677233.48451.484-521.355-550.968-144.452-338-82.387-92.774-57.161
EPS -0.44-0.33-0.74-0.28-0.38-0.29-0.33-0.30.37-0.290.0160.250.068-0.69-0.69-0.24-0.56-0.14-0.15-0.095
EPS Diluted -0.44-0.33-0.74-0.28-0.38-0.29-0.33-0.30.37-0.290.0160.250.068-0.69-0.69-0.24-0.56-0.14-0.15-0.095
EBITDA -13.438-9.914-21.421-7.324-10.11-7.46-8.675-7.956-7.88-8.254-3.546-8.8211.785-8.029-5.301-4.44-5.968-2.51-2.455-1.668
EBITDA Ratio 0000-5.693000-254.194-266.258-114.387-284.54857.581-259-171-143.226-192.516-80.968-79.194-53.806